Bajaj Healthcare Ltd
Bajaj Healthcare Q2 FY26: Revenue ₹299.28 Cr, PAT ₹22.94 Cr
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Bajaj Healthcare Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.
The short version
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Quarterly EBITDA: ₹53.99 crore (HYE Sept 2025, pg.
From Bajaj Healthcare Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore.
- This shows an increase from ₹482.10 crore in FY 2024 to ₹562.01 crore in FY 2025 full year, indicating growth.
- Profitability statement shows EBITDA of ₹53.99 crore for HYE Sept 2025.
- No explicit quarter-on-quarter or year-on-year percentage change in revenue or volumes is provided.
- Revenue mix shows a continuation of a strong domestic presence (~76-84%) and APIs contribution (~83-89%) in FY24, FY25, and HYE Sept 25.
2 more points from Bajaj Healthcare Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Bajaj Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Peptide Synthesis Plant: State-of-the-art facility with ~250 kg/annum capacity, commercializing by March 2026.
- New R&D Infrastructure: 10,000+ sq. ft. center in Savli, expected operational by May 2026, accommodating 100+ researchers.
- Oncology API Plant: Under construction, expected ready by 2027 at Nashik.
- Alkaloid Extraction Plant: Commissioned in Vadodara, Gujarat; processes 250 MTPA Opium Gum and 2500 MTPA Poppy Straw (2024).
2 more points from Bajaj Healthcare Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Bajaj Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Bajaj Healthcare Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Bajaj Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹166 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bajaj Healthcare Ltd's management said in earlier quarters
Arthneeti Pro · Annual
Bajaj Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bajaj Healthcare Ltd Q2 FY26 results?
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Quarterly EBITDA: ₹53.99 crore (HYE Sept 2025, pg.
What is Bajaj Healthcare Ltd share price analysis?
Bajaj Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,148 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bajaj Healthcare Ltd planning capital expenditure?
Peptide Synthesis Plant: State-of-the-art facility with ~250 kg/annum capacity, commercializing by March 2026.
Keep Bajaj Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.